ELOX Eloxx Pharmaceuticals, Inc.

NASDAQ
$10.69

Eloxx Pharmaceuticals, Inc. (ELOX) is expected to report earnings on February 12, 2027, before the market open. The stock has had a Post-Earnings Announcement Drift (PEAD) of -19.6% since its last earnings release on November 13, 2026.

Eloxx Pharmaceuticals Reported Earnings
Monday, November 16, 2026 · 7:00 AM ET
Earnings Date
4th Quarter, Dec 2026
Feb 12
Friday · 6:00 AM ET
Earnings Whisper
-
vs -
Volatility
Enter your expectations below to reveal the current volatility.
Trend Analysis
Expectation
Earnings
Price action
Signals
Score
Sentiment
Grade
Life Cycle
Call Analysis
Earnings-AVWAP $11.46

Sign in or subscribe to unlock sentiment, short interest, and technical indicators.

About Eloxx Pharmaceuticals, Inc.

Eloxx Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing novel RNA-modulating drug candidates (designed to be eukaryotic ribosomal selective glycosides) that are formulated to treat rare and ultra-rare premature stop codon diseases.

Sector

Healthcare

Industry

Biotechnology

Charts powered in part by Lightweight Charts™ by TradingView.